Generalized Myasthenia Gravis (gMG) Clinical Trials

8 recruitingLast updated: May 21, 2026

There are 8 actively recruiting generalized myasthenia gravis (gmg) clinical trials across 12 countries. Studies span Early Phase 1, Phase 2, Phase 3, Phase 4. Top locations include Miami, Florida, United States, Chattanooga, Tennessee, United States, Amherst, New York, United States. Updated daily from ClinicalTrials.gov.


Generalized Myasthenia Gravis (gMG) Trials at a Glance

8 actively recruiting trials for generalized myasthenia gravis (gmg) are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Early Phase 1 with 1 trial, with the heaviest enrollment activity in Miami, Chattanooga, and Amherst. Lead sponsors running generalized myasthenia gravis (gmg) studies include argenx, Alexion Pharmaceuticals, Inc., and AstraZeneca.

Browse generalized myasthenia gravis (gmg) trials by phase

About Generalized Myasthenia Gravis (gMG) Clinical Trials

Looking for clinical trials for Generalized Myasthenia Gravis (gMG)? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Generalized Myasthenia Gravis (gMG) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Generalized Myasthenia Gravis (gMG) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting

A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy

Generalized Myasthenia Gravis (gMG)gMG
argenx100 enrolled30 locationsNCT07595653
Recruiting

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

Rare DiseasesGeneralized Myasthenia Gravis (gMG)
AstraZeneca450 enrolled6 locationsNCT07247279
Recruiting

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Myasthenia GravisGeneralized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis+3 more
argenx70 enrolled10 locationsNCT07294170
Recruiting
Phase 2

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Myasthenia GravisGeneralized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis+3 more
argenx70 enrolled9 locationsNCT07284420
Recruiting

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

PregnancyParoxysmal Nocturnal Hemoglobinuria, PNHUltomiris-exposed Pregnant/ Postpartum+3 more
Alexion Pharmaceuticals, Inc.75 enrolled7 locationsNCT06312644
Recruiting
Phase 4

A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

New Onset Generalized Myasthenia Gravis (gMG)
argenx30 enrolled18 locationsNCT06909214
Recruiting
Phase 3

Zilucoplan for Severe gMG Exacerbations

Generalized Myasthenia Gravis (gMG)
Miriam Freimer15 enrolled1 locationNCT07215949
Recruiting
Early Phase 1

GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)

Generalized Myasthenia Gravis (gMG)
Daishi Tian6 enrolled1 locationNCT07058298